In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5139-5145

  Hagen, Ferry ^a,b   Illnait Zaragozi, Maria Teresa ^c   Bartlett, Karen H ^d   Swinne, Daniëlle ^e   Geertsen, Erik ^f   Klaassen, Corné H W ^f   Boekhout, Teun ^a,b   Meis, Jacques F ^f  

^a CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^f CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ISAVUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CRYPTOCOCCUS GATTII; FUNGUS ISOLATION; GENOTYPE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM ANALYSIS; ANIMALS; ANTIFUNGAL AGENTS; CRYPTOCOCCUS GATTII; ENVIRONMENTAL MICROBIOLOGY; FLUCONAZOLE; FLUCYTOSINE; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; NITRILES; PYRIDINES; PYRIMIDINES; TRIAZOLES;

EID: 78649651789     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00746-10     Document Type: Article

References (33)

1. Bartlett, K. H., S. E. Kidd, and J. W. Kronstad. 2008. The emergence of Cryptococcus gattii in British Columbia and the Pacific Northwest. Curr. Infect. Dis. Rep. 10:58-65.
2. Boekhout, T., B. Theelen, M. Diaz, J. W. Fell, W. C. Hop, E. C. Abeln, F. Dromer, and W. Meyer. 2001. Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology 147:891-907.
3. Bolano, A., S. Stinchi, R. Preziosi, F. Bistoni, M. Allegrucci, F. Baldelli, A. Martini, and G. Cardinali. 2001. Rapid methods to extract DNA and RNA from Cryptococcus neoformans. FEMS Yeast Res. 1:221-224.
4. Bovers, M., F. Hagen, E. E. Kuramae, H. L. Hoogveld, F. Dromer, G. St.-Germain, and T. Boekhout. 2008. AIDS patient death caused by novel Cryptococcus neoformans x C. gattii hybrid. Emerg. Infect. Dis. 14:1105-1108.
5. Bovers, M., F. Hagen, E. E. Kuramae, M. R. Diaz, L. Spanjaard, F. Dromer, H. L. Hoogveld, and T. Boekhout. 2006. Unique hybrids between the fungal pathogens Cryptococcus neoformans and Cryptococcus gattii. FEMS Yeast Res. 6:599-607.
6. Bovers, M., F. Hagen, E. E. Kuramae, and T. Boekhout. 2008. Six monophyletic lineages identified within Cryptococcus neoformans and Cryptococcus gattii by multi-locus sequence typing. Fungal Genet. Biol. 45:400-421.
7. Bovers, M., F. Hagen, and T. Boekhout. 2008. Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex. Rev. Iberoam. Micol. 25:S4-S12.
8. Byrnes, E. J., R. J. Bildfell, S. A. Frank, T. G. Mitchell, K. A. Marr, and J. Heitman. 2009. Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J. Infect. Dis. 199:1081-1086.
9. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Datta, K., K. H. Bartlett, R. Baer, E. J. Byrnes, E. Galanis, J. Heitman, L. Hoang, M. J. Leslie, L. MacDougall, S. S. Magill, M. G. Morshed, K. A. Marr, and the Cryptococcus gattii Working Group of the Pacific Northwest. 2009. Spread of Cryptococcus gattii into Pacific Northwest region of the United States. Emerg. Infect. Dis. 15:1185-1191.
11. Dromer, F., C. Bernede-Bauduin, D. Guillemot, O. Lortholary, and the French Cryptococcosis Study Group. 2008. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One 3:e2870.
12. Gomez-Lopez, A., O. Zaragoza, M. Dos Anjos Martins, M. C. Melhem, J. L. Rodriguez-Tudela, and M. Cuenca-Estrella. 2008. In vitro susceptibility of Cryptococcus gattii clinical isolates. Clin. Microbiol. Infect. 14:727-730.
13. Hagen, F., A. G. Burggraaf, A. Kamermans, J. Sweere, K. Tintelnot, D. Swinne, F. Dromer, R. Iatta, M. T. Montagna, J. M. Torres-Rodriguez, M. A. Viviani, A. Velegraki, M. F. Colom Valiente, M. Gari-Toussaint, and T. Boekhout. 2009. The occurrence of the primary pathogenic yeast Cryptococcus gattii in Europe. Mycoses 52(Suppl. 1):57.
14. Illnait-Zaragozi, M. T., G. F. Martínez, I. Curfs-Breuker, C. M. Fernández, T. Boekhout, and J. F. Meis. 2008. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob. Agents Chemother. 52:1580-1582.
15. Iqbal, N., E. E. DeBess, R. Wohrle, B. Sun, R. J. Net, A. M. Ahlquist, T. Chiller, and S. R. Lockhart. 2010. Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii from the Pacific Northwest of the United States. J. Clin. Microbiol. 48:539-544.
16. Kidd, S. E., F. Hagen, R. L. Tscharke, M. Huynh, K. H. Bartlett, M. Fyfe, L. Macdougall, T. Boekhout, K. J. Kwon-Chung, and W. Meyer. 2004. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc. Natl. Acad. Sci. U. S. A. 101:17258-17263.
17. Kwon-Chung, K. J., and J. E. Bennett. 1984. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am. J. Epidemiol. 120:123-130.
18. Kwon-Chung, K. J., I. Polacheck, and J. E. Bennett. 1982. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J. Clin. Microbiol. 15:535-537.
19. Ma, H., and R. C. May. 2009. Virulence in Cryptococcus species. Adv. Appl. Microbiol. 67:131-190.
20. Meyer, W., D. M. Aanensen, T. Boekhout, M. Cogliati, M. R. Diaz, M. C. Esposto, M. Fisher, F. Gilgado, F. Hagen, S. Kaocharoen, A. P. Litvintseva, T. G. Mitchell, S. P. Simwami, L. Trilles, M. A. Viviani, and K. J. Kwon- Chung. 2009. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med. Mycol. 47:561-570.
21. Meyer, W., A. Castañeda, S. Jackson, M. Huynh, E. Castañeda, and the IberoAmerican Cryptococcal Study Group. 2003. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg. Infect. Dis. 9:189-195.
22. Morera-López, Y., J. M. Torres-Rodríguez, T. Jiménez-Cabello, and T. Baró- Tomás. 2005. Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med. Mycol. 43:505-510.
23. Ngamskulrungroj, P., F. Gilgado, J. Faganello, A. P. Litvintseva, A. L. Leal, K. M. Tsui, T. G. Mitchell, M. H. Vainstein, and W. Meyer. 2009. Genetic diversity of the Cryptococcus species complex suggests that Cryptococcus gattii deserves to have varieties. PLoS One 4:e5862.
24. Perfect, J. R., W. E. Dismukes, F. Dromer, D. L. Goldman, J. R. Graybill, R. J. Hamill, T. S. Harrison, R. A. Larsen, O. Lortholary, M. H. Nguyen, P. G. Pappas, W. G. Powderly, N. Singh, J. D. Sobel, and T. C. Sorrell. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50:291-322.
25. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, G. V. Doern, and D. J. Diekema. 2005. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol. 43:2163-2167.
26. Sorrell, T. C. 2001. Cryptococcus neoformans variety gattii. Med. Mycol. 39:155-168.
27. Springer, D. J., and V. Chaturvedi. 2010. Projecting global occurrence of Cryptococcus gattii. Emerg. Infect. Dis. 16:14-20.
28. Thompson, G. R., III, A. W. Fothergill, N. P. Wiederhold, A. C. Vallor, B. L. Wickes, and T. F. Patterson. 2008. Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. Antimicrob. Agents Chemother. 52:2959-2961.
29. Thompson, G. R., III, N. P. Wiederhold, A. W. Fothergill, A. C. Vallor, B. L. Wickes, and T. F. Patterson. 2009. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob. Agents Chemother. 53:309-311.
30. Trilles, L., B. Fernandez-Torres, M. dos Santos Lazera, B. Wanke, and J. Guarro. 2004. In vitro antifungal susceptibility of Cryptococcus gattii. J. Clin. Microbiol. 42:4815-4817.
31. Van Elden, L. J., A. M. Walenkamp, M. M. Lipovsky, P. Reiss, J. F. Meis, S. de Marie, J. Dankert, and A. I. Hoepelman. 2000. Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. AIDS 14:2787-2788.
32. Velagapudi, R., Y. P. Hsueh, S. Geunes-Boyer, J. R. Wright, and J. Heitman. 2009. Spores as infectious propagules of Cryptococcus neoformans. Infect. Immun. 77:4345-4355.
33. Yamazumi, T., M. A. Pfaller, S. A. Messer, A. Houston, R. J. Hollis, and R. N. Jones. 2000. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:2883-2886.